Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.
Nguyen THM, Carreira PE, Sanchez-Luque FJ, Schauer SN, Fagg AC, Richardson SR, Davies CM, Jesuadian JS, Kempen MHC, Troskie RL, James C, Beaven EA, Wallis TP, Coward JIG, Chetty NP, Crandon AJ, Venter DJ, Armes JE, Perrin LC, Hooper JD, Ewing AD, Upton KR, Faulkner GJ. Nguyen THM, et al. Among authors: coward jig. Cell Rep. 2018 Jun 26;23(13):3730-3740. doi: 10.1016/j.celrep.2018.05.090. Cell Rep. 2018. PMID: 29949758 Free article.
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. He Y, et al. Oncogene. 2016 Jan 28;35(4):468-78. doi: 10.1038/onc.2015.101. Epub 2015 Apr 20. Oncogene. 2016. PMID: 25893298
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, Roche DK, Kennedy C, Chetty NP, Crandon AJ, Flatley C, Oliveira NB, Shannon CM, deFazio A, Tinker AV, Gilks CB, Gabrielli B, Brennan DJ, Coward JI, Armes JE, Perrin LC, Hooper JD. Harrington BS, et al. Br J Cancer. 2016 Feb 16;114(4):417-26. doi: 10.1038/bjc.2015.471. Epub 2016 Feb 4. Br J Cancer. 2016. PMID: 26882065 Free PMC article.
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Khan T, et al. Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869. Cancers (Basel). 2020. PMID: 32260077 Free PMC article.
Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context.
Samoylovich A, Jennings B, Shannon C, Coward JI, Lourie R, Riordan J, Lai NA, van Driel WJ, Cabraal N, Jagasia N, Chetty N, Naidu S, Perrin LC, Barry SC. Samoylovich A, et al. Aust N Z J Obstet Gynaecol. 2023 Oct;63(5):702-708. doi: 10.1111/ajo.13694. Epub 2023 May 31. Aust N Z J Obstet Gynaecol. 2023. PMID: 37259677
Mucinous ovarian cancer: A therapeutic review.
Xu W, Rush J, Rickett K, Coward JI. Xu W, et al. Crit Rev Oncol Hematol. 2016 Jun;102:26-36. doi: 10.1016/j.critrevonc.2016.03.015. Epub 2016 Mar 19. Crit Rev Oncol Hematol. 2016. PMID: 27083591 Review.
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group; Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD. Anglesio MS, et al. Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22. Clin Cancer Res. 2011. PMID: 21343371 Clinical Trial.
PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.
Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT; Australian Prostate Cancer BioResource; Craik DJ, Parton RG, Russell PJ, Hill MM. Moon H, et al. Oncogene. 2014 Jul 3;33(27):3561-70. doi: 10.1038/onc.2013.315. Epub 2013 Aug 12. Oncogene. 2014. PMID: 23934189
46 results